Pegetron [peginterferon alfa-2b] Redipen [ribavirin] Prospective Optimal Weight-Based Dosing Response Program.
Phase of Trial: Phase IV
Latest Information Update: 06 Feb 2016
At a glance
- Drugs Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms RediPEN
- Sponsors Merck & Co; Schering-Plough
- 06 Feb 2016 Results (post hoc pooled analysis of PoWer and RediPEN studies) published in the European Journal of Clinical Microbiology and Infectious Diseases (n = 1242).
- 31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2012 Planned number of patients changed from 1285 to 2320 as reported by ClinicalTrials.gov.